Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roundhill Glp-1 & Weight Loss ETF (OZEM)

Roundhill Glp-1 & Weight Loss ETF (OZEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Roundhill Investments
  • Assets Under Management 50,580,400
  • Shares Outstanding, K 1,420
  • 60-Month Beta 0.54
  • Price/Earnings ttm 0.00
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.053 on 12/30/24
  • Management Fee 0.59%

Options Overview Details

View History
  • Implied Volatility 24.57% (-0.02%)
  • Historical Volatility 24.71%
  • IV Percentile 27%
  • IV Rank 25.53%
  • IV High 53.23% on 04/09/25
  • IV Low 14.74% on 09/09/25
  • Expected Move (DTE 2) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 28
  • Volume Avg (30-Day) 32
  • Put/Call OI Ratio 1.57
  • Today's Open Interest 568
  • Open Int (30-Day) 489
  • Expected Range 35.62 to 35.62

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.51 +6.31%
on 12/17/25
36.49 -2.38%
on 12/30/25
+1.12 (+3.25%)
since 12/12/25
3-Month
27.34 +30.29%
on 10/22/25
36.49 -2.38%
on 12/30/25
+7.04 (+24.65%)
since 10/13/25
52-Week
20.01 +78.01%
on 04/09/25
36.49 -2.38%
on 12/30/25
+11.62 (+48.42%)
since 01/13/25

Most Recent Stories

More News
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver disease....

NVO : 59.64 (-0.37%)
OZEM : 35.62 (-0.31%)
PPH : 105.46 (-0.15%)
THNR : 25.98 (-0.75%)
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

Eli Lilly and Company LLY reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines, driven by strong demand for its blockbuster weight loss and diabetes drugs....

NVO : 59.64 (-0.37%)
OZEM : 35.62 (-0.31%)
IHE : 86.03 (+0.42%)
LLY : 1,077.19 (-0.35%)
MEDX : 33.43 (-0.35%)
PPH : 105.46 (-0.15%)
MEDI : 31.94 (+0.41%)
5 Sector ETFs Up 10% Despite February's Market Slump

Wall Street ended February on a dismal note, weighed down by economic slowdown concerns and Trump’s tariff plans. The tech-heavy Nasdaq Composite suffered its biggest monthly decline since April 2024,...

MUSQ : 28.17 (-0.46%)
SOCL : 58.29 (-0.40%)
OZEM : 35.62 (-0.31%)
SGDM : 78.20 (+0.77%)
NERD : 24.38 (-0.83%)
Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat

Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.

XLV : 156.74 (-0.41%)
OZEM : 35.62 (-0.31%)
LLY : 1,077.19 (-0.35%)
SPY : 693.77 (-0.20%)
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight-loss medicine...

OZEM : 35.62 (-0.31%)
IHE : 86.03 (+0.42%)
LLY : 1,077.19 (-0.35%)
MEDX : 33.43 (-0.35%)
PPH : 105.46 (-0.15%)
THNR : 25.98 (-0.75%)
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish

JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity.

XLV : 156.74 (-0.41%)
OZEM : 35.62 (-0.31%)
LLY : 1,077.19 (-0.35%)
SPY : 693.77 (-0.20%)
Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 Projections

The pharma giant expects continued growth for Mounjaro and Zepbound this year, supported by expanded manufacturing capacity and new market launches.

XLV : 156.74 (-0.41%)
OZEM : 35.62 (-0.31%)
LLY : 1,077.19 (-0.35%)
SPY : 693.77 (-0.20%)
Eli Lilly, Novo Nordisk Shares Climb Premarket As Biden Administration Mulls Medicare, Medicaid Covering For Obesity Drugs: Retail Unmoved

he new proposal would expand access to medications for obesity, and help an estimated 3.4 million Americans with Medicare.

NVO : 59.64 (-0.37%)
OZEM : 35.62 (-0.31%)
LLY : 1,077.19 (-0.35%)
IBB : 171.32 (-0.05%)
XBI : 123.85 (-0.06%)
Novo Nordisk Stock Falls Despite Strong Q3 Weight-Loss Drug Sales: Retail Shrugs Off Weakness

Novo Nordisk’s injectable weight-loss drug Wegovy sales climbed 79% year-over-year but overall sales growth was a touch soft.

NVO : 59.64 (-0.37%)
OZEM : 35.62 (-0.31%)
AVDE : 84.83 (-0.50%)
Tap the Weight-Loss Drug Market With These ETFs

The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are...

NVO : 59.64 (-0.37%)
OZEM : 35.62 (-0.31%)
LLY : 1,077.19 (-0.35%)
HRTS : 35.90 (-0.53%)
RHHBY : 53.3400 (+0.26%)
THNR : 25.98 (-0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The Roundhill GLP-1 and Weight Loss ETF seeks to provide exposure to companies involved in the development of pharmaceutical drugs and/or supplements that can be utilized to help individuals lose weight, maintain an ideal weight, and/or maintain body composition during weight loss.

See More

Top 10 Holdings

Name % Holdings

See More

Key Turning Points

3rd Resistance Point 36.62
2nd Resistance Point 36.34
1st Resistance Point 35.98
Last Price 35.62
1st Support Level 35.33
2nd Support Level 35.05
3rd Support Level 34.69

See More

52-Week High 36.49
Last Price 35.62
Fibonacci 61.8% 30.19
Fibonacci 50% 28.25
Fibonacci 38.2% 26.31
52-Week Low 20.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar